A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
← catalyst calendarNCT07541287 · readout ≤ 896 d
Sponsored by Jade Biosciences, Inc. (industry) · JBIO — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
30estimated
Sites
9
Countries
New Zealand, South Korea, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-19 | actual | When the study began enrolling |
| Primary completion | Jan 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- IgA Nephropathy
Intervention
- Drug: JADE101
Primary outcome
what the primary-completion date above is the date OFIncidence of treatment-emergent adverse events (safety and tolerability)
measured Day 1 through 100 weeks
Permalink · JBIO's whole pipeline · Catalyst calendar · Every registered study · What changed